Pasireotide companion diagnostic - OctreoPharm

Drug Profile

Pasireotide companion diagnostic - OctreoPharm

Alternative Names: 68Ga-pasireotide tetraxetan; DOTA-SOM; Gallium-68-pasireotide tetraxetan; OPS 101

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OctreoPharm Sciences
  • Class Cyclic peptides; Imaging agents; Macrocyclic compounds; Oligopeptides; Peptidomimetics; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • No development reported Neuroendocrine tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuroendocrine-tumours(Diagnosis) in Germany (Parenteral)
  • 27 Oct 2011 Preclinical trials in Neuroendocrine tumours (diagnosis) in Germany (Parenteral)
  • 27 Oct 2011 Pasireotide companion diagnostic receives Orphan Drug status for Neuroendocrine tumours (diagnosis) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top